A Phase I, Observational Study of Cannabidiol as a New Treatment for Drug Resistant Epilepsies
Study objectives: To determine the tolerability and optimal dose of CBD as an adjunct treatment in children and young adults with severe drug resistant epilepsy. Secondarily to also determine if there is a change in seizure frequency from baseline.
Number of subjects: 25
All subjects will be on the study drug, that is added to current anti epileptic drug regimen, for 1 year after reaching maximal dosage. Seizure diaries will be kept throughout the study to monitor for any reduction in seizure frequency.